Lack of proportionality. Seven specifications of public interest that override post-approval commercial interests on limited access to clinical data

Trials

Volumn 13, Issue , 2012, Pages

  Strech, Daniel ^a,b   Littmann, Jasper ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL PRACTICE; COMMERCIAL PHENOMENA; DRUG INDUSTRY; HEALTH INSURANCE; HUMAN; NOTE; PRACTICE GUIDELINE; PUBLIC HEALTH; SOCIAL MARKETING; ACCESS TO INFORMATION; CLINICAL TRIAL (TOPIC); CONFLICT OF INTEREST; EDITORIAL; EVIDENCE BASED MEDICINE; GOVERNMENT REGULATION; HEALTH CARE COST; HEALTH CARE POLICY; LEGAL ASPECT; PATIENT SAFETY; PRODUCT SAFETY; RISK ASSESSMENT; STANDARD;

ACCESS TO INFORMATION; CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; CONSUMER PRODUCT SAFETY; DRUG INDUSTRY; EVIDENCE-BASED MEDICINE; GOVERNMENT REGULATION; GUIDELINES AS TOPIC; HEALTH CARE SECTOR; HEALTH POLICY; HUMANS; PATIENT SAFETY; RISK ASSESSMENT;

EID: 84863097953     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-13-100     Document Type: Note

References (27)

1. Dickersin K, Rennie D. Registering clinical trials. JAMA 2003, 290(4):516-523. 10.1001/jama.290.4.516, 12876095.
2. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Ann Intern Med 2004, 141(6):477-478.
3. Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008, 358(3):252-260. 10.1056/NEJMsa065779, 18199864.
4. Rising K, Bacchetti P, Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation. PLoS Med 2008, 5(11):e217. discussion e217, 10.1371/journal.pmed.0050217, 2586350, 19067477.
5. Wieseler B, McGauran N, Kaiser T. Finding studies on reboxetine: a tale of hide and seek. BMJ 2010, 341:c4942. 10.1136/bmj.c4942, 20940211.
6. Gotzsche PC, Jorgensen AW. Opening up data at the European Medicines Agency. BMJ 2011, 342:d2686. 10.1136/bmj.d2686, 21558364.
7. EMA HMA/EMA recommendations on transparency. November 2010) http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/12/WC500099536.pdf p. 2. In.; 2010, EMA.
8. NICE Guide to the methods of technology appraisal. June 2008) http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf Appendix D, p. 72. In.; 2008, NICE.
9. Eichler HG, Abadie E, Breckenridge A, Leufkens H, Rasi G. Open clinical trial data for all? A view from regulators. PLoS Med 2012, 9(4):e1001202. 10.1371/journal.pmed.1001202, 3323505, 22505851.
10. International Working Group on Transparency and Accountability in Drug Regulation Statement 1996, Health Action International,Dag Hammarskjöld Foundation, Amsterdam, International Working Group on Transparency and Accountability in Drug Regulation.
11. Lexchin J. Transparency in Drug Regulation: Mirage or Oasis? In 2004, Canadian Centre for Policy Alternatives, Ottawa.
12. Lexchin J, Mintzes B. Transparency in drug regulation: mirage or oasis?. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2004, 171(11):1363-1365.
13. Hemminki E, McPherson K. Value of drug-licensing documents in studying the effect of postmenopausal hormone therapy on cardiovascular disease. Lancet 2000, 355(9203):566-569. 10.1016/S0140-6736(99)03432-7, 10683020.
14. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. The New England Journal of Medicine 2007, 356(24):2457-2471. 10.1056/NEJMoa072761, 17517853.
15. Jefferson T, Jones M, Doshi P, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009, 339:b5106. 10.1136/bmj.b5106, 2790574, 19995812.
16. Doshi P. Neuraminidase inhibitors-the story behind the Cochrane review. BMJ 2009, 339:b5164. 10.1136/bmj.b5164, 19995813.
17. Sträter B. Europäische Rahmenbedingungen für den Schutz von geistigem Eigentum an Zulassungsunterlagen. Teil 1: Rahmenbedingungen für den Schutz des Zulassungsdossiers. Pharm Ind 2011, 73(8):1450-1458.
18. Foundation ABIM. ACP-ASIM Foundation, European Federation of Internal Medicine: Medical professionalism in the new millennium: a physicians' charter. Lancet 2002, 359(9305):520-522.
19. Delamothe T. Whose data are they anyway?. BMJ 1996, 312(7041):1241-1242. 10.1136/bmj.312.7041.1241, 2351079, 8634604.
20. CIOMS International Ethical Guidelines for Biomedical Research Involving Human Subjects 2002, Council for International Organizations of Medical Sciences, Geneva, CIOMS.
21. WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects 2008, World Medical Association, Seoul, WMA.
22. Smith GD. Increasing the accessibility of data. BMJ 1994, 308(6943):1519-1520. 10.1136/bmj.308.6943.1519, 2540522, 8019302.
23. Levin LA, Palmer JG. Institutional review boards should require clinical trial registration. Arch Intern Med 2007, 167(15):1576-1580. 10.1001/archinte.167.15.1576, 17698679.
24. Kopp IB. Implications of publication bias on guideline development and appraisal. Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen 2011, 105(3):201-206. 10.1016/j.zefq.2011.03.010, 21530910.
25. European Science Foundation Implementation of Medical Research in Clinical Practice 2011, European Science Foundation (ESF), Strasbourg, European Science Foundation.
26. Caplan AL. Will evidence ever be sufficient to resolve the challenge of cost containment?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011, 29(15):1946-1948.
27. WHO The world health report - Health systems financing: the path to universal coverage 2010, World Health Organization (WHO), Geneva, WHO.